Clinical Trial Detail

NCT ID NCT02208375
Title mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
Recruitment Active, not recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

fallopian tube carcinoma

ovarian serous carcinoma

endometrial adenocarcinoma

peritoneal carcinoma

triple-receptor negative breast cancer

Therapies

Capivasertib + Olaparib

Olaparib + Vistusertib

Age Groups: adult senior

No variant requirements are available.